Sign In
Buy KZR
$7.29
+0 (+0%)
At Close: Jun 10, 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, FORA, SLNO, and APLS
11:01am, Tuesday, 14'th Apr 2026
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders a
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
01:34pm, Friday, 10'th Apr 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
07:26am, Tuesday, 07'th Apr 2026
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Kezar (NASDAQ: KZR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction w
Lifecore Biomedical (NASDAQ:LFCR) and Kezar Life Sciences (NASDAQ:KZR) Head-To-Head Review
01:23am, Thursday, 02'nd Apr 2026
Kezar Life Sciences (NASDAQ: KZR - Get Free Report) and Lifecore Biomedical (NASDAQ: LFCR - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the tw
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
01:35pm, Monday, 30'th Mar 2026
NEW YORK, March 30, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and
MILWAUKEE, March 30, 2026 /PRNewswire/ -- Ademi LLP is investigating Kezar (NASDAQ: KZR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Kezar Life Sciences, Inc. (NASDAQ: KZR) to Aurinia Pharmaceuticals Inc. for $6.955 in cash per sh
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
08:00am, Monday, 30'th Mar 2026
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of “Reduce” by Brokerages
04:28am, Monday, 16'th Mar 2026
Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) has earned a consensus recommendation of "Reduce" from the six analysts that are presently covering the stock, Marketbeat.com reports. Two inv
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
09:00am, Thursday, 12'th Mar 2026
PARIS & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Biotech--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of
BML Capital Management LLC Has $2.81 Million Holdings in Kezar Life Sciences, Inc. $KZR
04:23am, Monday, 23'rd Feb 2026
BML Capital Management LLC boosted its holdings in Kezar Life Sciences, Inc. (NASDAQ: KZR) by 13.5% in the third quarter, according to its most recent filing with the SEC. The institutional investor o
Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Consensus Rating of “Reduce” from Analysts
03:29am, Thursday, 19'th Feb 2026
Shares of Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) have been given an average rating of "Reduce" by the six research firms that are currently covering the firm, Marketbeat.com reports
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
06:01am, Friday, 09'th Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know
01:00pm, Monday, 05'th Jan 2026
Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Average Recommendation of “Reduce” from Brokerages
01:26am, Wednesday, 31'st Dec 2025
Shares of Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) have received an average recommendation of "Reduce" from the six ratings firms that are currently covering the firm, MarketBeat Rati
